Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 78   

Articles published

ARNA 4.51 -0.24 (-5.05%)
price chart
Will Arena Pharmaceuticals (ARNA) Disappoint on Q4 Earnings?
Arena Pharmaceuticals, Inc. (ARNA - Snapshot Report) is scheduled to report fourth-quarter 2014 results on Mar 2. Last quarter, the company posted a positive earnings surprise of 61.54%.
Will Arena Pharmaceuticals (ARNA) Disappoint on Q4 Earnings? - Analyst Blog  Nasdaq
Arena Pharmaceuticals' Belviq Set To Surge In 2015
It might also be said that, when examining cyclical trends in any kind of market, those that learn from history may be better positioned to take advantage of a repeat performance.
Why Arena Pharmaceuticals, Inc. Shares Jumped 24% in January
What: Shares of Arena Pharmaceuticals (NASDAQ: ARNA ) , a biopharmaceutical company primarily focused on developing therapies for weight management and to treat autoimmune diseases, jumped 24% in January per S&P Capital IQ after reporting ...
Arena Pharmaceuticals, Inc. Analyst Rating Update
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has received a Neutral rating from research analysts at Zacks with a rating of 3. The company has been rated an average of 2.29 by 7 Wall Street Analysts.
Price Target Update on Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) should head towards $6.83 per share according to 6 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $5 per share.
Arena's Belviq Scripts Spike - Maintaining This Trajectory Important
Arena (NASDAQ:ARNA) investors had something to celebrate this past week when script sales of the anti-obesity drug Belviq were released by IMS Health.
Arena Pharmaceuticals Inc. (ARNA) Jumps 6.08% on February 25
Arena Pharmaceuticals Inc. ($ARNA) was among the biggest gainers on the Russell 2000 for Wednesday February 25 as the stock popped 6.08% to $4.71, representing a gain of $0.27 per share.
Arena Pharmaceuticals, Inc. Registers High Short Interest
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA): Each share of Arena Pharmaceuticals Inc is priced at $4.67, which is 36.5% below the 52-week high.
Arena's Belviq Slows At A Bad Time
New prescription numbers have been released by IMS Health for Belviq (see Table 1), the anti-obesity agent from Arena Pharmaceuticals (NASDAQ:ARNA). The 2.5% week-to-week improvement is a slight improvement over the previous year's gain of 1.0%.
Analyst Rating Update on Arena Pharmaceuticals, Inc.
Analysts at Zacks have given a short term rating of hold on Arena Pharmaceuticals (NASDAQ:ARNA) with a rank of 3. The counter has received an average rating of 2.29 from 7 brokerage firms.